Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finance Watch: Bitcoin For Biopharma? Agenus Gives BEST A Shot

Executive Summary

Investors in a February Biotech Electronic Security Token (BEST) offering will be able to put their money behind a single Agenus asset – the PD-1 inhibitor AGEN2034. Also, financial and strategic updates from Gossamer, Aduro, Novo's REPAIR Impact Fund and more.

Advertisement

Related Content

Deals Shaping The Medical Industry, January 2019
Asia Deal Watch: Boost For Esperion's Cholesterol Candidate As Daiichi Brought On Board
Gilead Extends Push Into Oncology With Agenus R&D Pact
Keeping Track: FDA Starts November With A Bang
Deal Watch: Takeda Teams With Molecular Templates On Anti-CD38 Approach To Multiple Myeloma
ACR Notebook: Lilly's Baricitinib Differentiates On Pain, Ironwood's Duzallo Progress, Corbus Nears Phase III
Deal Watch: AstraZeneca Offloads US Anesthesiology Portfolio To Aspen
Finance Watch: OncoMed Cuts Costs To Conserve Capital While Public, Private Peers Raise Cash
Argos And Agenus Trials Pile On Fresh Cancer Vaccine Disappointments
Aduro gets $200m as Novartis steps up immuno-oncology

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124580

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel